Is Biological Products Industry Alliance Legit?

The Biological Products Industry Alliance (BPIA) demonstrates consistent financial growth and strong asset accumulation over the past decade. Revenue has steadily increased from $246,778 in 2014 to $882,035 in 2023, with assets growing from $155,801 to $1,973,202 in the same period. This indicates effective financial management and an expanding operational capacity. The organization consistently spends less than it earns, contributing to its robust asset base. BPIA exhibits excellent spending efficiency, with program expenses consistently forming the vast majority of total expenditures. For instance, in 2023, expenses were $586,613 against revenue of $882,035, showing a healthy surplus. The absence of reported officer compensation across all filings suggests that executive leadership may be volunteer-based or compensated through other means not categorized as direct officer compensation, which is a notable aspect of its financial structure. Transparency appears strong given the consistent filing of IRS Form 990s and the clear financial trends. The organization's NTEE code S41 (Industry & Trade Associations) aligns with its name, suggesting a clear mission focus. The lack of reported officer compensation, while potentially indicating volunteer leadership, also means there's no direct executive compensation to scrutinize, which can be seen as a positive for resource allocation.